ACE and Ventricular arrhythmia: This study’s primary objective is to assess the occurrence of ventricular arrhythmia and anti-tachycardia pacing events that occurred over six months after starting angiotensin-converting enzyme inhibitor/angiotensin receptor blocker treatments compared with the sacubitril/valsartan treatment [42].